Sign In
Buy MO
Altria Earnings Calls
| Release date | Apr 30, 2026 |
| EPS estimate | $1.25 |
| EPS actual | $1.32 |
| EPS Surprise | 5.60% |
| Revenue estimate | 4.578B |
| Revenue actual | 4.758B |
| Revenue Surprise | 3.94% |
| Release date | Jan 29, 2026 |
| EPS estimate | $1.32 |
| EPS actual | $1.30 |
| EPS Surprise | -1.52% |
| Revenue estimate | 5.033B |
| Revenue actual | 5.079B |
| Revenue Surprise | 0.91% |
| Release date | Oct 30, 2025 |
| EPS estimate | $1.44 |
| EPS actual | $1.45 |
| EPS Surprise | 0.694% |
| Revenue estimate | 5.293B |
| Revenue actual | 5.251B |
| Revenue Surprise | -0.787% |
| Release date | Jul 30, 2025 |
| EPS estimate | $1.39 |
| EPS actual | $1.44 |
| EPS Surprise | 3.60% |
| Revenue estimate | 5.189B |
| Revenue actual | 5.29B |
| Revenue Surprise | 1.94% |
Last 4 Quarters for Altria
Below you can see how MO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 30, 2025 |
| Price on release | $61.50 |
| EPS estimate | $1.39 |
| EPS actual | $1.44 |
| EPS surprise | 3.60% |
| Date | Price |
|---|---|
| Jul 24, 2025 | $59.61 |
| Jul 25, 2025 | $59.84 |
| Jul 28, 2025 | $58.72 |
| Jul 29, 2025 | $59.36 |
| Jul 30, 2025 | $61.50 |
| Jul 31, 2025 | $61.94 |
| Aug 01, 2025 | $61.78 |
| Aug 04, 2025 | $61.94 |
| Aug 05, 2025 | $62.52 |
| 4 days before | 3.17% |
| 4 days after | 1.66% |
| On release day | 0.715% |
| Change in period | 4.88% |
| Release date | Oct 30, 2025 |
| Price on release | $57.13 |
| EPS estimate | $1.44 |
| EPS actual | $1.45 |
| EPS surprise | 0.694% |
| Date | Price |
|---|---|
| Oct 24, 2025 | $64.67 |
| Oct 27, 2025 | $63.74 |
| Oct 28, 2025 | $63.28 |
| Oct 29, 2025 | $61.97 |
| Oct 30, 2025 | $57.13 |
| Oct 31, 2025 | $56.38 |
| Nov 03, 2025 | $56.67 |
| Nov 04, 2025 | $57.31 |
| Nov 05, 2025 | $57.16 |
| 4 days before | -11.66% |
| 4 days after | 0.0525% |
| On release day | -1.31% |
| Change in period | -11.61% |
| Release date | Jan 29, 2026 |
| Price on release | $59.76 |
| EPS estimate | $1.32 |
| EPS actual | $1.30 |
| EPS surprise | -1.52% |
| Date | Price |
|---|---|
| Jan 23, 2026 | $61.91 |
| Jan 26, 2026 | $62.98 |
| Jan 27, 2026 | $63.62 |
| Jan 28, 2026 | $63.13 |
| Jan 29, 2026 | $59.76 |
| Jan 30, 2026 | $61.99 |
| Feb 02, 2026 | $62.23 |
| Feb 03, 2026 | $64.16 |
| Feb 04, 2026 | $65.16 |
| 4 days before | -3.47% |
| 4 days after | 9.04% |
| On release day | 3.73% |
| Change in period | 5.25% |
| Release date | Apr 30, 2026 |
| Price on release | $72.64 |
| EPS estimate | $1.25 |
| EPS actual | $1.32 |
| EPS surprise | 5.60% |
| Date | Price |
|---|---|
| Apr 24, 2026 | $66.88 |
| Apr 27, 2026 | $66.00 |
| Apr 28, 2026 | $67.80 |
| Apr 29, 2026 | $68.20 |
| Apr 30, 2026 | $72.64 |
| May 01, 2026 | $74.55 |
| May 04, 2026 | $73.41 |
| May 05, 2026 | $72.79 |
| May 06, 2026 | $70.17 |
| 4 days before | 8.61% |
| 4 days after | -3.40% |
| On release day | 2.63% |
| Change in period | 4.92% |
Altria Earnings Call Transcript Summary of Q1 2026
Altria reported a strong start to 2026 with adjusted diluted EPS up 7.3% in Q1. Key financial and operational takeaways: smokeable products delivered solid income growth (adjusted OCI up 6.3%; margins expanded to 65.1%) supported by 6.3% net price realization and moderation in cigarette volume declines. Marlboro strengthened in the premium segment; PM USA's total-portfolio approach helped Basic gain share in the discount segment. Oral tobacco: Helix/on! shipments grew ~18% (>46 million cans) and on! PLUS began national shipping in March to ~100,000 stores (85% of nicotine pouch category volume), though on! retail share was down year-over-year. Altria highlighted the FDA pilot pathway for on! PLUS and expects additional authorizations within the 180-day statutory timeline. E-vapor: company sees signs of moderation in illicit flavored disposable growth driven by increased enforcement and supply disruption; Altria advocates faster, more predictable FDA authorization combined with sustained enforcement to restore a compliant market. Other items: ABI equity earnings rose to $160M (+9.6%); Altria returned significant capital — ~$1.8B in dividends and $280M for 4.5M shares repurchased in Q1 ( ~$72M remaining on the program ); retired just over $1B debt; leverage at ~1.9x. Management reaffirmed 2026 adjusted diluted EPS guidance of $5.56–$5.72 (growth of 2.5%–5.5% vs. 2025) while noting macro uncertainty (higher gas prices, consumer discretionary pressure). CEO Billy Gifford announced this will be his final earnings call.
